Xintela AB (publ) (XINT.ST)
SEK 0.32
(-0.63%)
SEK 0.32
(-0.63%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -57.23 Million SEK | 14.64% |
| 2022 | -69.06 Million SEK | -58.56% |
| 2021 | -43.55 Million SEK | -28.5% |
| 2020 | -33.89 Million SEK | 10.91% |
| 2019 | -38.04 Million SEK | -57.19% |
| 2018 | -24.2 Million SEK | -10.35% |
| 2017 | -21.93 Million SEK | -28.29% |
| 2016 | -17.09 Million SEK | -48.49% |
| 2015 | -11.51 Million SEK | -284.62% |
| 2014 | -2.99 Million SEK | -33.88% |
| 2013 | -2.23 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -10.8 Million SEK | 16.21% |
| 2024 Q2 | -10.39 Million SEK | 3.79% |
| 2023 Q1 | -15.2 Million SEK | 34.53% |
| 2023 Q4 | -12.89 Million SEK | -4.8% |
| 2023 FY | -58.95 Million SEK | 14.64% |
| 2023 Q3 | -12.3 Million SEK | 29.9% |
| 2023 Q2 | -17.55 Million SEK | -15.41% |
| 2022 Q4 | -23.22 Million SEK | -87.11% |
| 2022 Q3 | -12.41 Million SEK | 28.8% |
| 2022 Q2 | -17.43 Million SEK | -9.04% |
| 2022 Q1 | -15.98 Million SEK | -31.93% |
| 2022 FY | -69.06 Million SEK | -58.56% |
| 2021 FY | -43.55 Million SEK | -28.5% |
| 2021 Q4 | -12.11 Million SEK | -12.09% |
| 2021 Q1 | -8.92 Million SEK | 20.13% |
| 2021 Q3 | -10.81 Million SEK | 7.57% |
| 2021 Q2 | -11.69 Million SEK | -31.01% |
| 2020 FY | -33.89 Million SEK | 10.91% |
| 2020 Q1 | -7.51 Million SEK | 24.59% |
| 2020 Q3 | -7.06 Million SEK | 13.23% |
| 2020 Q4 | -11.17 Million SEK | -58.26% |
| 2020 Q2 | -8.14 Million SEK | -8.29% |
| 2019 Q4 | -9.96 Million SEK | -25.21% |
| 2019 Q3 | -7.96 Million SEK | 25.3% |
| 2019 Q2 | -10.65 Million SEK | -12.64% |
| 2019 Q1 | -9.46 Million SEK | -16.74% |
| 2019 FY | -38.04 Million SEK | -57.19% |
| 2018 FY | -24.2 Million SEK | -10.35% |
| 2018 Q4 | -8.1 Million SEK | -104.59% |
| 2018 Q3 | -3.96 Million SEK | 18.53% |
| 2018 Q2 | -4.86 Million SEK | 33.2% |
| 2018 Q1 | -7.27 Million SEK | -9.86% |
| 2017 Q4 | -6.62 Million SEK | -35.65% |
| 2017 FY | -21.93 Million SEK | -28.29% |
| 2017 Q1 | -5.4 Million SEK | -17.13% |
| 2017 Q2 | -5.01 Million SEK | 7.28% |
| 2017 Q3 | -4.88 Million SEK | 2.61% |
| 2016 FY | -17.09 Million SEK | -48.49% |
| 2016 Q1 | -3.62 Million SEK | 26.68% |
| 2016 Q4 | -4.61 Million SEK | -52.71% |
| 2016 Q3 | -3.02 Million SEK | 42.27% |
| 2016 Q2 | -5.23 Million SEK | -44.42% |
| 2015 Q3 | -1.81 Million SEK | 34.06% |
| 2015 Q2 | -2.75 Million SEK | -15.76% |
| 2015 Q1 | -2.37 Million SEK | 0.0% |
| 2015 FY | -11.51 Million SEK | -284.62% |
| 2015 Q4 | -4.94 Million SEK | -172.71% |
| 2014 FY | -2.99 Million SEK | -33.88% |
| 2013 FY | -2.23 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 77.011% |
| Ziccum AB (publ) | -21.56 Million SEK | -165.482% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -248.991% |
| BioArctic AB (publ) | 252.64 Million SEK | 122.656% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -6673.728% |
| Mendus AB (publ) | -100.65 Million SEK | 43.132% |
| Genovis AB (publ.) | 54.22 Million SEK | 205.558% |
| Intervacc AB (publ) | -93.57 Million SEK | 38.835% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -268.992% |
| Active Biotech AB (publ) | -46.48 Million SEK | -23.135% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 417.83% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | -3.286% |
| Aptahem AB (publ) | -10.1 Million SEK | -466.446% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 82.197% |
| Kancera AB (publ) | -65.04 Million SEK | 11.998% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 57.481% |
| Fluicell AB (publ) | -26.87 Million SEK | -112.947% |
| Saniona AB (publ) | -81.06 Million SEK | 29.392% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -362.679% |
| Biovica International AB (publ) | -126.07 Million SEK | 54.599% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | -34.662% |
| AcouSort AB (publ) | -17.48 Million SEK | -227.317% |
| Abliva AB (publ) | -96.54 Million SEK | 40.715% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 82.377% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -1533.039% |
| OncoZenge AB (publ) | -15.9 Million SEK | -259.942% |
| Amniotics AB (publ) | -29.07 Million SEK | -96.877% |
| 2cureX AB (publ) | -36.36 Million SEK | -57.407% |
| CombiGene AB (publ) | -36.3 Million SEK | -57.658% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -290.97% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 85.11% |
| Camurus AB (publ) | 532.35 Million SEK | 110.752% |
| Corline Biomedical AB | -1.78 Million SEK | -3101.23% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 68.336% |
| Isofol Medical AB (publ) | -41.68 Million SEK | -37.317% |
| I-Tech AB | 24.43 Million SEK | 334.246% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 92.741% |
| Cyxone AB (publ) | -21.66 Million SEK | -164.244% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 45.984% |
| Biosergen AB | -27.26 Million SEK | -109.932% |
| Cantargia AB (publ) | -290.01 Million SEK | 80.264% |
| NextCell Pharma AB | -43.17 Million SEK | -32.581% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 68.336% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -234.798% |
| Nanologica AB (publ) | -69.96 Million SEK | 18.188% |
| SynAct Pharma AB | -224.49 Million SEK | 74.504% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | -29.568% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -138.947% |
| LIDDS AB (publ) | -40.67 Million SEK | -40.724% |
| Lipum AB (publ) | -37.25 Million SEK | -53.643% |
| BioInvent International AB (publ) | -369.94 Million SEK | 84.528% |
| Alzinova AB (publ) | -16.52 Million SEK | -246.435% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 77.416% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -795.288% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 50.259% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -184.215% |
| Simris Alg AB (publ) | -36.63 Million SEK | -56.239% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 60.948% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 81.561% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 48.394% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -394.882% |